Summary Using in vitro techniques, bone marrow (BM) function has been studied in 25 patients in complete remission and at least one year after the completion of MVPP chemotherapy for Hodgkin's disease. The numbers of granulocyte/macrophage (GM-CFC) and fibroblastoid (CFU-F) progenitors were significantly lower than controls and there was no evidence of any improvement with time (median months off treatment was 30 for GM-CFC and 34 for CFU-F). In long-term BM culture production of haemopoietic cells were strikingly lower in the post-MVPP group and the development of adherent stromal cell populations was also significantly less. In addition, the yield of GM-CFC in adherent layers after four weeks of culture was significantly lower than in controls. We conclude that following MVPP chemotherapy and in apparently disease free and haematologically normal individuals there is evidence of impaired BM function up to nine years after the completion of treatment. These abnormalities may be relevant to the known increased risk of acute non-lymphocytic leukaemias in this group of patients and are likely to render the BM less able to withstand subsequent insults such as further chemotherapy or infection. The eventual development of BM failure is also a possibility and long-term follow-up of these patients is essential.
The introduction of multi-agent cytotoxic chemotherapy given intensively on an intermittent basis by De Vita et al. (1980) in the early 1960s has revolutionised the treatment of generalised Hodgkin's disease (HD). The long-term survival of patients treated with MOPP or MVPP for stages IIIB and IV Hodgkin's disease is approximately 60% (Nicholson et al., 1970; Sutcliffe et al., 1978; Wagstaff et al., 1988) ; a figure which compares with less than 5% during the period in which single agent therapy was in vogue. Such welcome improvements in treatment have resulted in an increasing number of patients surviving long enough for any chronic effects of cytotoxic therapy on normal tissues to become manifest and myocardial (Bonadonna et al., 1969) , pulmonary (Sostmann et al., 1977) , and gonadal damage (Shalet, 1980) following chemotherapy are all well described.
Acute myelosuppression is the most common cause of treatment delay or dose reduction in cancer chemotherapy and the long term effects of these treatments on bone marrow (BM) function are therefore of interest. Using a mouse model, Morley and Blake (1974) described three distinct haematological phases following treatment with busulphan. The first phase, acute myelosuppression, resulted in a small mortality due to infection. The second and longest phase was one of apparent haematological normality characterised by normal BM cellularity and peripheral blood counts. In the third phase, mortality was high due to infection or haemorrhage secondary to BM aplasia or, in only a few animals, acute leukaemia. Eighty per cent of the treated mice had died by the 240th day; a period of roughly one-third of a normal life span in mice. Such universal and profound effects have fortunately not been observed in patients following conventional chemotherapy but acute non-lymphocytic leukaemias (ANLL), sometimes preceded by myelodysplastic states, do occur. In a study of 473 patients treated with MOPP and/or radiotherapy for HD at the NCI (Tester et al., 1974) , the estimated risk of ANLL at ten years was 2% following chemotherapy alone, 6% following chemotherapy and radiotherapy as primary treatment and 9% after combined modality therapy used in the salvage setting. Other groups (Boivin et al., 1981; Coleman et al., 1982; Glickman et al., 1982; Pedersen-Bjegaard et al., 1982) have published similar results although higher risks (6%) of secondary ANLL have also been reported following chemotherapy alone (Coltman et al., 1982) . In spite of these clear suggestions that cytotoxic drugs may have important long-term effects on the bone marrow only one study of BM function after chemotherapy for HD involving five patients has been published (Bull et al., 1975 (Myers et al., 1984) ], were added between 5 x 104 and 5 x 105 nucleated BM cells and sufficient IMDM to make a final volume of 4.5 ml in a sterile plastic universal container. Then, 0.5 ml of molten agar (0.33%) was mixed thoroughly with the cell suspension and 1 ml aliquots of this mixture were pipetted into each of three small culture dishes (Falcon, New Jersey, USA). Triplicate culture plates were cooled rapidly at 4°C for about 10 min and then incubated at 37°C in a humidified atmosphere containing 5% carbon dioxide in air. After 11 days, GM colonies (aggregates of 50 cells or more) were counted.
Colony forming units fibroblastoid (CFU-F) This quantita-
tive assay which detects a normal component of the marrow stroma (Friedenstein et al., 1974) , was performed by adding 1.5 x 106 nucleated BM cells to IMDM plus 15% pretested FCS to make a final volume of 15 ml in a 50 ml capacity tissue culture flask (Falcon, New Jersey, USA). The mixture was divided equally between three flasks which, after gassing with 5% CO2 in air were stoppered and incubated at 37°C. After 11 days the supernatant was discarded, the adherent cells washed with phosphate buffered saline and then fixed with methanol for two minutes. After staining with 1% crystal violet, colonies (aggregates of 50 cells or more) were counted.
Long-term bone marrow culture Cultures were established with 1.5 x 10' nucleated BM cells in 10 ml of IMDM plus 10% pretested FCS, 10% pretested horse serum and 5 x l0-' M hydrocortisone in 50 ml capacity culture flask (Coutinho et al., 1986) . After gassing with 5% CO2 in air, the flask was stoppered and incubated 33°C in the dark. Flasks were fed weekly by removing half the supernatant and replacing with fresh medium. A nucleated cell count and GM-CFC assay were performed on the culture fluid removed and from these data the cell count and GM-CFC per total supernatant were calculated.
Adherent layer confluence was assessed by examining multiple fields of the flask base under low power and estimated the total area of plastic covered by stromal cells expressed as a fraction of the total flask base area.
Cell counts and GM-CFC assays were also performed on adherent layer cells following trypsination (Coloumbel et al., 1983) . The supernatant of four week old cultures was removed and the adherent layer gently washed with IMDM to remove any remaining non-adherent cells. Two to three ml of a 0.25% solution of trypsin were added to the flask and incubated at 37°C for no longer than five minutes until the adherent layer fragmented. (0) These results are consistent with the supernatant data where clear differences in the numbers of total nucleated cells were only becoming apparent at week 4 in contrast to the numbers of GM-CFC which were exhibiting maximal differences between the two groups by this time (Figures 3a and b) . another with neutropenic sepsis following further chemotherapy for relapsed HD. The number of both GM-CFC and CFC-F in samples of bone marrow were significantly lower in patients following MVPP than in controls. Interestingly, there was no correlation between either score and the time elapsed (up to nine years) after completion of chemotherapy, indicating that recovery with time may not occur. This is in agreement with data derived from murine models where, after a variety of chemotherapeutic regimens, no further recovery is observed during the remaining life span of the mouse once the acute recovery phase is over (reviewed by Testa et al., 1985) . In long-term culture, BM from controls performed markedly better than that from chemotherapy-treated patients both in terms of total nucleated cells and of GM-CFC measured in the supernatant over time. A significant difference between the groups was also seen in the number of GM-CFC from trypsinised adherent layer at four weeks, confirming that the differences observed in numbers of supernatant GM-CFC were not due to differential rates of release of these cells from the adherent layer, but rather to a real shortfall in production.
Adherent layer formation after six weeks of LTC was strikingly subnormal in the post-chemotherapy population. Extension of the adherent layer is achieved in part by fibroblastoid cells, a component of the stromal cell compartment and detectable by the CFU-F assay. The sigificantly lower number of CFU-F found in BM from chemotherapy-treated patients therefore accords well with the reduced adherent layer confluence of these samples in LTC and both sets of data raise the possibility of a stromal cell defect, in addition to the probable stem cell damage which has long been recognised. This is relevant because haematopoiesis both in vivo and in long-term BM culture occurs within a complex microenvironment composed of various stromal cell types which probably exert local control on cell growth and differentiation (Dexter et al., 1984) . Damage to this compartment may therefore have important implications for the regulation of haemopoiesis.
Acute myelotoxicity is an invariable accompaniment of cytotoxic therapy sometimes leading to infective or haemorrhagic complications and delays or curtailment of subsequent treatment. Once chemotherapy is completed, however, peripheral blood counts usually recover rapidly and there is a return to apparent haematological normality. Despite this, patients achieving prolonged survival following treatment have a far higher incidence of actue non-lymphocytic leukaemia than the general population, a fact which is generally thought to be related to their previous exposure to cytotoxic agents. If this is the case, sub-clinical evidence of disturbed BM function some time after the completion of chemotherapy might reasonably be expected. In the mouse, Morley et al. (1975) identified chronic BM damage affecting both the stem and stromal cell compartments during the period of 'haematological latency' following treatment with busulphan. In man, however, only a few studies of bone marrow function some time after the completion of chemotherapy for lymphoproliferative disease are reported in the literature.
Bull et al., reporting in 1975, found normal levels of GM-CFC 1.5-6 years after treatment with MOPP for HD in five patients and concluded that there was no evidence of permanent damage to these granulocyte precursors following intensive chemotherapy. It is of note that, only one of the treated patients in our study had a level of GM-CFC in BM that fell outside the normal range but nevertheless a highly significant difference was observed when a comparison was made between the two populations. Hartmann et al. (1979) found a reduction in the number of GM-CFC in 18 children treated for non-Hodgkin's lymphoma between 1 and 19 months following chemotherapy but in a study of 30 children treated for acute lymphoblastic leukaemia (ALL) no such reduction was identified between 6 months and 3.5 years after treatment (Inoue et al., 1980) . Haworth et al. (1982) also found no evidence of chronic BM damage as assessed by GM-CFC levels in 37 patients who had received standard amounts of chemotherapy for ALL but in a further six patients who received additional cytotoxic treatment for testicular or haematological relapse a significant reduction in GM-CFC was observed. In a later study of 20 children in unmaintained remission three months to three years after completion of more intensive chemotherapy for ALL, a significantly lower number of GM-CFC was found in the BM and in long-term culture . Furthermore, patients who had received additional treatment for relapse had a tendency to lower levels of GM-CFC than those receiving standard treatment and there was no evidence of any improvement in levels of GM-CFC with time.
Our study is the first to examine the long-term effects of MVPP chemotherapy for Hodgkin's disease on BM function in a large sample of patients and using several in vitro techniques. We have found that in apparently disease free and haematologically normal individuals there is evidence of BM damage, which may not be reversible, up to several years after the completion of treatment. These abnormalities coincide with normal numbers of cells in the peripheral blood, presumably achieved through compensatory mechanisms which come into play during stress haematopoiesis, and which may also achieve normal production of mature cells from a damaged BM during steady state . However, these defects are likely to result in an impaired response to periods of increased demand on the BM, such as infection or further chemotherapy, and may be relevant to the evolution of secondary leukaemias in this group of patients. Moreover, the effects of ageing on these populations are not yet known. In previously untreated mice some workers have found evidence of reduced haemopoietic function in old compared to young animals (Mauch et al., 1982) but this has not been confirmed by other groups (Schofield, 1986) . However, following a severe insult to the BM such as that resulting from cytotoxic therapy, any ageing process might become more readily apparent and result in clinically important syndromes related to BM hypoplasia or aplasia similar to the effects seen in the busulphan-treated mice of Morley and Blake (1974) .
We conclude that following curative chemotherapy for HD, bone marrow function may be chronically impaired, a possibility not excluded by a normal peripheral blood count. Whether the in vitro evidence of chronic BM damage described here will, after many years, be translated into clinically relevant cytopenias of the peripheral blood is unknown and we consider that the long-term surveillance of these patients is essential.
